This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Walzer, P. D.
Right arrow Articles by Sidman, C. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Walzer, P. D.
Right arrow Articles by Sidman, C. L.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, 02 1997, 251-258, Vol 41, No. 2
Copyright © 1997 by the American Society for Microbiology. All rights reserved.

Immunodeficient and immunosuppressed mice as models to test anti- Pneumocystis carinii drugs

PD Walzer, J Runck, P Steele, M White, MJ Linke and CL Sidman
Research Service, Veterans Affairs Medical Center, Cincinnati, Ohio 45220, USA.

Congenitally immunodeficient and immunosuppressed normal mice with naturally acquired Pneumocystis carinii infection were compared as models for testing anti-P. carinii drugs. Among the immunodeficient mice, mice with severe combined immunodeficiency disease (scid), which lack B and T cells, had higher levels of P. carinii pneumonia than did microMT mice, which lack K cells. Normal mice administered dexamethasone in the drinking water had more extensive pneumocystosis than mice administered parenteral methylprednisolone or hybridoma cells making a monoclonal antibody to CD4 cells. The standard anti-P. carinii drugs trimethoprim (TMP)-sulfamethoxazole (SMX), pentamidine, and atovaquone, which work well in rats and humans, worked well in the mice. Clindamycin and primaquine were effective in the scid and microMT mice but not in the immunosuppressed normal mice. High doses of epiroprim, an analog of TMP, appeared to enhance the activities of low doses of SMX and dapsone, while high doses of TMP did not; however, further studies are needed before definitive conclusions about the actions of these drugs can be drawn. Taken together, the data obtained in this study support the growing body of literature suggesting that the mouse is a valid alternative to the rat as a model for testing anti- P. carinii drugs. Additional differences involving the activities of individual drugs in these models will probably emerge as more experience is gained.


This article has been cited by other articles:

  • Cushion, M. T., Walzer, P. D., Ashbaugh, A., Rebholz, S., Brubaker, R., Vanden Eynde, J. J., Mayence, A., Huang, T. L. (2006). In Vitro Selection and In Vivo Efficacy of Piperazine- and Alkanediamide-Linked Bisbenzamidines against Pneumocystis Pneumonia in Mice.. Antimicrob. Agents Chemother. 50: 2337-2343 [Abstract] [Full Text]  
  • Vestereng, V. H., Kovacs, J. A. (2004). Inability of Pneumocystis organisms to incorporate bromodeoxyuridine suggests the absence of a salvage pathway for thymidine. Microbiology 150: 1179-1182 [Abstract] [Full Text]  
  • Thullen, T. D., Ashbaugh, A. D., Daly, K. R., Linke, M. J., Steele, P. E., Walzer, P. D. (2004). Sensitized Splenocytes Result in Deleterious Cytokine Cascade and Hyperinflammatory Response in Rats with Pneumocystis Pneumonia despite the Presence of Corticosteroids. Infect. Immun. 72: 757-765 [Abstract] [Full Text]  
  • Walzer, P. D., Ashbaugh, A. (2002). Use of Terbinafine in Mouse and Rat Models of Pneumocystis carinii Pneumonia. Antimicrob. Agents Chemother. 46: 514-516 [Abstract] [Full Text]  
  • Walzer, P. D., Ashbaugh, A., Collins, M., Cushion, M. T. (2001). In Vitro and In Vivo Effects of Quinupristin-Dalfopristin against Pneumocystis carinii. Antimicrob. Agents Chemother. 45: 3234-3237 [Abstract] [Full Text]  
  • Cirioni, O., Giacometti, A., Barchiesi, F., Scalise, G. (2000). Inhibition of growth of Pneumocystis carinii by lactoferrins alone and in combination with pyrimethamine, clarithromycin and minocycline. J Antimicrob Chemother 46: 577-582 [Abstract] [Full Text]  
  • Walzer, P. D. (1999). Immunological Features of Pneumocystis carinii Infection in Humans. CVI 6: 149-155 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»